Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

Sureda, Anna; Arranz, Reyes; Iriondo, A; Carreras, Enric; Lahuerta, Juan José; Garcı́a-Conde, J; Jarque, Isidro; Caballero, Marı́a Dolores; Ferra, C.; López, Ángel L.; García-Laraña, José; Cabrera, Rafael; Carrera, Dolores; Ruiz-Romero, M D; León, Ángel; Rifón, J.; Dı́az-Mediavilla, Joaquı́n; Mataix, R; Morey, Miguel; Moraleda, José Marı́a; Altés, Albert; López‐Guillermo, Armando; Serna, Javier de la; Fernández-Rañada, J M; Sierra, Jorge; Conde, Eulogio; Linformas, Grupo Español de

doi:10.1200/jco.2001.19.5.1395

Cited by 222 publications

(162 citation statements)

References 43 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…In our study, 3y OS was 70% in all patients who underwent autologous HSCT (Fig. 1A), and was comparable to that in previous studies [4,12,13]. In addition, OS was favorable even in patients who underwent autologous HSCT in the disease status other than CR, although the disease status was associated with OS, which was similar to the results in many other studies [4,12,13].…”

Section: Discussionsupporting

confidence: 91%

“…This study was planned by the Adult Lymphoma Working Group of JSHCT, and was approved by the data management committee of TRUMP and by the institutional review board of Nagoya University School of Medicine. 12 Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan; 13 Department of Hematopoietic Stem Cell Transplantation Data Management and Biostatistics, Nagoya University School of Medicine, Nagoya, Japan; 14 Cancer Center, Shimane University Hospital, Shimane, Japan Statistical considerations. Differences between groups were examined using Fisher's exact test for categorical variables.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

et al. 2014

View full text Add to dashboard Cite

on behalf of the Adult Lymphoma Working Group of the Japanese Society for Hematopoietic Cell TransplantationThe optimal treatment strategy with the use of hematopoietic stem cell transplantation (HSCT) for relapsed and refractory Hodgkin lymphoma (HL) remains unclear. We performed a retrospective analysis using registry data from the Japanese Society for Hematopoietic Cell Transplantation. Adult patients with HL who underwent a first autologous or a first allogeneic HSCT between 2002 and 2009 were included. Patients who underwent HSCT in first complete remission (CR) were excluded. Autologous and allogeneic HSCT were performed in 298 and 122 patients, respectively. For autologous HSCT, overall survival at 3 years (3yOS) was 70%, and sex, age, disease status, and performance status (PS) at HSCT were prognostic factors. OS was favorable even in patients who underwent autologous HSCT in disease status other than CR. For allogeneic HSCT, 3yOS was 43%, and sex and PS at HSCT were prognostic factors. Disease status at HSCT, previous autologous HSCT, and conditioning intensity did not affect OS. Moreover, graft-versus-host disease did not affect progression-free survival or relapse/progression rate. A first allogeneic HSCT without a previous autologous HSCT was performed in 40 patients. 3yOS was 45%, and was significantly inferior to that in patients who underwent their first autologous HSCT. This result was retained after the correction by the different patient characteristics according to the type of HSCT. In conclusion, autologous HSCT is effective in prolonging survival in patients with relapsed and refractory HL. Allogeneic HSCT might be beneficial even to relapsed HL after autologous HSCT, although establishing the role of allogeneic HSCT remains a challenge.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Methodsmentioning

confidence: 99%

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…41,62 Pre-HCT radiotherapy has been shown to be an adverse risk factor for SN. 59,60,62 Among 133 patients with aplastic anemia undergoing allogeneic HCT, pre-HCT immunosuppressive therapy with cyclosporine (a group 1 carcinogen according to the International Agency for Research on Cancer) 124 was associated with five-fold higher rates of SN. 75 …”

Section: Disease- and Transplant-related Risk Factorsmentioning

confidence: 99%

“…The data suggest an interaction with age, with higher risk of SN in younger recipients exposed to TBI compared with older patients. 39,125 However, the role of TBI in SN risk remains unresolved, with six publications providing strong evidence of increased SN risk from TBI exposure, 16,17,32,46,49,60 and eight studies failing to identify an association between TBI and SN. 22,24,33,37,38,41,59,69 …”

Section: Disease- and Transplant-related Risk Factorsmentioning

confidence: 99%

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report

Morton

Saber

Baker

et al. 2017

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Subsequent neoplasms (SN) following hematopoietic cell transplantation (HCT) cause significant patient morbidity and mortality. Risks for specific SN types vary substantially, with particularly elevated risks for post-transplant lymphoproliferative disorders, myelodysplastic syndrome/acute myeloid leukemia, and squamous cell malignancies. This consensus document provides an overview of the current state of knowledge regarding SN after HCT and recommends priorities and approaches to overcome challenges and gaps in understanding. Numerous factors have been suggested to impact risk, including patient-related (e.g., age), primary disease-related (e.g., disease type, pre-HCT therapies), and HCT-related characteristics (e.g., type and intensity of conditioning regimen, stem cell source, development of graft-versus-host disease). However, gaps in understanding remain for each of these risk factors, particularly for patients receiving HCT in the current era due to substantial advances in clinical transplantation practices. Additionally, the influence of non-transplant-related risk factors (e.g., germline genetic susceptibility, oncogenic viruses, lifestyle factors) is poorly understood. Clarification of the magnitude of SN risks and identification of etiologic factors will require large-scale, long-term, systematic follow-up of HCT survivors with detailed clinical data. Most investigations of the mechanisms of SN pathogenesis after HCT have focused on immune drivers. Expansion of our understanding in this area will require interdisciplinary laboratory collaborations utilizing measures of immune function and availability of archival tissue from SN diagnoses. Consensus-based recommendations for optimal preventative, screening, and therapeutic approaches have been developed for certain SN after HCT, whereas for other SN, general population guidelines are recommended. Further evidence is needed to specifically tailor preventative, screening, and therapeutic guidelines for SN after HCT, particularly for unique patient populations. Accomplishment of this broad research agenda will require increased investment in systematic data collection with engagement from patients, clinicians, and interdisciplinary scientists in order to reduce the burden of SN in the rapidly growing population of HCT survivors.

show abstract

“…The treatment of refractory or relapsed disease has been investigated extensively and high-dose chemotherapy (HDCT) with autologous stem cell support has become the standard protocol in patients with chemo-sensitive disease after induction therapy. Indeed, several nonrandomized studies [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] have suggested a better outcome for patients receiving HDCT. These results have been confirmed by two randomized studies [18,19] comparing a single course of HDCT to conventional chemotherapy in chemo-sensitive patients.…”

Section: Introductionmentioning

confidence: 99%

Tandem high‐dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study

et al. 2006

View full text Add to dashboard Cite

We designed a prospective study to evaluate the feasibility and efficacy of tandem highdose chemotherapy (HDCT) in the treatment of refractory or relapsed Hodgkin's lymphoma (HL). Thirty-two patients were treated with salvage chemotherapy (IGEV, ifosfamide, gemcitabine, and vinorelbine) and chemo-sensitive patients received a first HDCT course with melphalan 200 mg/m 2 (MEL200) and a second BEAM course. The median time interval between the two HDCT courses was 66 days. The median number of reinfused CD34 + cells was 4.7 x 10 6 /kg after MEL200 and 5.8 x 10 6 /kg after BEAM. The hematological reconstitution after both HDCT courses did not differ. No grade III or IV renal, hepatic, lung, cardiac, and neurological toxicity was observed. Severe (grade III and IV) oral mucositis was the most prominent complication affecting 60 and 50% of patients after MEL200 and BEAM, respectively. Fever of unknown origin occurred in 65 and 70% of patients after MEL200 and BEAM, respectively. One patient died from septic shock during the aplasia period following BEAM. In an intention-to-treat analysis, the overall response rate increased after each stage of protocol, ranging from 47% to 65% and 75% after IGEV, MEL200, and BEAM, respectively. Tandem HDCT is feasible and effective in patients with relapsed or refractory HL. Am. J. Hematol. 82:122-127, 2007. V V C 2006 Wiley-Liss, Inc.

show abstract

Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

Cited by 222 publications

References 43 publications

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report

Tandem high‐dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study

Contact Info

Product

Resources

About